RxDoctor Payments Data

Ashokvardhan Veldanda, MD

Family Medicine · Manahawkin, NJNPI 1780630764

Payments from drug & device makers

$838in general payments, 2019–2025

Across 54 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$165
  • Boehringer Ingelheim$141
  • Novo Nordisk$125
  • Johnson & Johnson$67
  • Abbott$47
  • Mallinckrodt Hospital Products Inc.$44
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$838 in reported general payments places this provider in the 60th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$212,500
Medicare patients
482
Services billed
3,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide83$162,785
OzempicSemaglutide80$155,192
TrulicityDulaglutide58$125,690
EliquisApixaban77$100,128
FarxigaDapagliflozin Propanediol72$91,593
JardianceEmpagliflozin59$78,913
Bydureon BciseExenatide Microspheres51$71,276
GlyxambiEmpagliflozin/Linagliptin41$67,566
TradjentaLinagliptin53$62,896
XareltoRivaroxaban43$55,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$32,085
Xultophy 100-3.6Insulin Degludec/Liraglutide16$30,380
Breo ElliptaFluticasone/Vilanterol53$28,036
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$22,612
Soliqua 100-33Insulin Glargine/Lixisenatide24$21,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6$125$348,356179 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$141$209,375153 claims
Lilly USA, LLCTrulicity$165$125,69058 claims
AstraZenecaFarxiga$24$91,59372 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$33$82,733123 claims
Johnson & JohnsonXarelto$67$55,30643 claims
MerckJanuvia, Janumet$28$34,02526 claims
Astellas Pharma US IncMyrbetriq$28$16,93718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Manahawkin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →